|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:administered_by
|
gptkb:Hepatitis_B_vaccine
gptkb:DTa_P_vaccine
gptkb:varicella_vaccine
injection
|
|
gptkbp:associated_with
|
herd immunity
|
|
gptkbp:available_in
|
most countries
|
|
gptkbp:average_temperature
|
2 to 8 degrees Celsius
|
|
gptkbp:contains
|
live attenuated viruses
|
|
gptkbp:contraindication
|
immunocompromised individuals
severe allergic reaction
|
|
gptkbp:developed_by
|
gptkb:Merck_&_Co.
|
|
gptkbp:dosage_form
|
two doses
|
|
gptkbp:first_introduced
|
gptkb:1971
|
|
gptkbp:has
|
vaccine information statement
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
measles, mumps, rubella (MMR) vaccine
|
|
gptkbp:increased
|
immunity
|
|
gptkbp:influenced_by
|
public health campaigns
|
|
gptkbp:is_considered
|
safe and effective
|
|
gptkbp:is_discussed_in
|
gptkb:literature
|
|
gptkbp:is_effective_against
|
over 90% for measles
over 78% for mumps
over 97% for rubella
|
|
gptkbp:is_evaluated_by
|
clinical trials
|
|
gptkbp:is_informed_by
|
gptkb:scientific_research
|
|
gptkbp:is_linked_to
|
reduction in hospitalizations
reduction in mortality rates
autism controversy
|
|
gptkbp:is_monitored_by
|
vaccine registries
|
|
gptkbp:is_part_of
|
immunization programs
combination vaccines
|
|
gptkbp:is_promoted_by
|
health organizations
|
|
gptkbp:is_protected_by
|
gptkb:rubella
gptkb:measles
mumps
|
|
gptkbp:is_recommended_by
|
gptkb:CDC
gptkb:WHO
|
|
gptkbp:is_recommended_for
|
gptkb:children
|
|
gptkbp:is_subject_to
|
regulatory approval
vaccine hesitancy
|
|
gptkbp:part_of
|
childhood vaccination schedule
|
|
gptkbp:reduces
|
measles outbreaks
mumps outbreaks
rubella outbreaks
|
|
gptkbp:requires
|
informed consent
booster shots in some cases
|
|
gptkbp:side_effect
|
fever
rash
thrombocytopenia
swelling of glands
febrile seizures
|
|
gptkbp:suitable_for
|
pregnant women
people with certain medical conditions
|
|
gptkbp:bfsParent
|
gptkb:paramyxovirus
|
|
gptkbp:bfsLayer
|
6
|